Skip to main content

Amneal Pharmaceuticals, Inc.

AMRX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001723128

In the last 90 days, Amneal Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 3 sales; 311 institutions reported holding it in 13F filings for Q2 2026, worth $2.82B in total; no superinvestor holds it.

Q1 2023 vs. Q4 2022

How the institutions holding Amneal Pharmaceuticals, Inc. changed between Q4 2022 and Q1 2023.

All holders in Q1 2023All holders in Q4 2022

13F holders of AMRX: Q4 2022 compared with Q1 2023
MeasureQ4 2022Q1 2023Change
Holders157145−12
Shares102.0M96.8M−5.19M (−5.1%)
Value$202.7M$134.7M−$68.0M (−33.5%)

New holders (9)

Institutions that held Amneal Pharmaceuticals, Inc. at the end of Q1 2023 but not at the end of Q4 2022.

Institutions new to AMRX in Q1 2023
InstitutionSharesValue% of portfolio
Nantahala Capital Management, LLC500,000$695.0K0.07%
Virtus Investment Advisers, Inc.44,480$61.8K0.04%
SG Americas Securities, LLC43,282$60.0K0.00%
Smith Anglin Financial, LLC30,300$42.1K0.01%
Qtron Investments LLC26,945$37.5K0.01%
Grantham, Mayo, Van Otterloo & Co. LLC23,100$32.1K0.00%
Commonwealth Equity Services, LLC13,025$18.0K0.00%
Virtus Fund Advisers, LLC6,941$9.65K0.07%
Simplex Trading, LLC485$00.00%

Sold out (21)

Institutions that held Amneal Pharmaceuticals, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.